CagriSema Mechanism Explainer

Why combining a long-acting amylin analogue with a GLP-1 agonist may produce more weight reduction than the GLP-1 agonist alone — and what the phase-3 evidence actually shows.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

What CagriSema is

CagriSema is a Novo Nordisk investigational medicine: a fixed-ratio combination of two peptides delivered together from a single subcutaneous injector pen once weekly.

Semaglutide — a GLP-1 receptor agonist. Already licensed as Wegovy (weight management) and Ozempic (T2D). See our semaglutide monograph.
Cagrilintide — a long-acting analogue of amylin, the pancreatic hormone co-secreted with insulin. Not licensed anywhere as of 2026-07. See our cagrilintide monograph.

The combination is being trialled at up to 2.4 mg + 2.4 mg per week — the same maintenance dose as Wegovy for the semaglutide component.

Why combine two peptides?

Amylin and GLP-1 both suppress appetite and slow gastric emptying, but they do so via partially independent central and peripheral pathways. Combining a long-acting agonist for each is expected to produce more than either alone — additive, not merely overlapping.

Practically, the two long-acting peptides share the same weekly cadence, so a fixed-ratio pen is possible. The Enebo 2021 phase-1b trial (Lancet, PMID 33894838) established that co-administration did not produce unexpected pharmacokinetic interactions — prerequisite for the fixed-ratio combination programme.

Two mechanistic axes, not one

Amylin axis (cagrilintide)

Native amylin binds the amylin receptor — a heterodimer of the calcitonin receptor and receptor-activity-modifying protein (RAMP) subunits, giving AMY1R, AMY2R and AMY3R subtypes. The satiety signal is transmitted principally via the area postrema and hindbrain (dorsal vagal complex). Amylin also directly suppresses glucagon secretion and slows gastric emptying.

Cagrilintide extends amylin's minutes-long half-life to roughly a week by lipid conjugation, sustained by albumin binding — the same approach that made semaglutide a once-weekly GLP-1 agonist.

Incretin axis (semaglutide)

Semaglutide binds the GLP-1 receptor, a class-B GPCR present on pancreatic β-cells, in the GI tract, and — importantly for weight — in the hypothalamus. Central appetite suppression via arcuate nucleus circuits and delayed gastric emptying via vagal afferents produce the appetite and food-intake reduction seen in the STEP and SUSTAIN programmes.

Additive, not synergistic

The word to avoid is synergistic. The REDEFINE 1 head-to-head data show CagriSema producing greater mean weight reduction than semaglutide 2.4 mg alone, but the effect is consistent with two partly-independent satiety pathways adding their individual signals, not with a supra-additive interaction. Calling it synergistic overstates what the trial evidence supports. See our page on why synergy is often assumed, not demonstrated.

Evidence base at a glance

Enebo 2021 (Lancet), phase 1b — PK / safety of cagrilintide + semaglutide 2.4 mg co-administration.
REDEFINE 1 (Garvey 2025, NEJM), phase 3 — obesity without T2D, 68 weeks, head-to-head vs semaglutide monotherapy and placebo.
REDEFINE 2 (Davies 2025, NEJM), phase 3 — obesity with T2D, 68 weeks.
REDEFINE 1 blood-pressure sub-analysis (Verma 2026, Hypertension) — pre-specified BP change analysis.
REIMAGINE 1-3 (Aroda / Buse / Rosenstock 2026, Lancet family), phase 3 — T2D populations.

Full citations on the cagrilintide monograph and the CagriSema stack review.

What the evidence does not (yet) show

Cardiovascular outcome benefit (a SELECT-equivalent trial is not published).
Multi-year safety and effectiveness.
Durability of weight loss after discontinuation.
Effects on muscle mass beyond DEXA endpoints in the primary papers.
Real-world effectiveness outside the trial populations.

UK regulatory context

As of 2026-07, cagrilintide has no UK MHRA marketing authorisation. CagriSema is not licensed by the MHRA, FDA, or EMA. Any UK-facing promotion of CagriSema as a weight-loss product would fall under the MHRA's rules on advertising unlicensed medicines — see our page on POM advertising in the UK and the weight-loss medicine advertising caution.

Semaglutide monotherapy IS licensed in the UK. Cagrilintide is not. The combination product's regulatory status is a distinct question from either component's, and Novo Nordisk's pathway is via the standard marketing-authorisation route — no application is public as of this page's last review.

Published: 2026-06-20Last updated: 2026-06-20Last reviewed: 2026-06-20

Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.